IndexIQ Advisors’s Gilead Sciences GILD Stock Holding History

IndexIQ Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$4.65M	Buy	78,287 +57,249	+272%	+$3.66M	0.16%	119
2021 Q4	$1.53M	Sell	21,038 -737	-3%	-$50.8K	0.05%	248
2021 Q3	$1.52M	Buy	21,775 +1,025	+5%	+$72K	0.05%	258
2021 Q2	$1.43M	Buy	20,750 +660	+3%	+$44.1K	0.05%	248
2021 Q1	$1.3M	Sell	20,090 -22,810	-53%	-$1.47M	0.05%	241
2020 Q4	$2.5M	Buy	42,900 +8,241	+24%	+$497K	0.09%	172
2020 Q3	$2.19M	Buy	34,659 +5,474	+19%	+$380K	0.09%	164
2020 Q2	$2.25M	Buy	29,185 +2,741	+10%	+$210K	0.1%	152
2020 Q1	$1.98M	Buy	26,444 +26,006	+5,937%	+$1.8M	0.09%	129
2019 Q4	$28K	Buy	+438	New	+$28.5K	﹤0.01%	574

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors's GILD Position: Q1 2022 in Review

IndexIQ Advisors increased its Gilead Sciences (GILD) stake by 272% in Q1 2022, buying an estimated $3.66M and bringing the position to 78,287 shares worth $4.65M. The position accounts for 0.16% of the portfolio, ranked #119.

IndexIQ Advisors first reported a position in GILD in Q4 2019 and has held it in 10 quarters since. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

IndexIQ Advisors held 78,287 shares of Gilead Sciences worth $4.65M as of Q1 2022.
IndexIQ Advisors bought 57,249 Gilead Sciences shares in Q1 2022, an estimated $3.66M.
Gilead Sciences made up 0.16% of IndexIQ Advisors's portfolio in Q1 2022, its #119 holding.
IndexIQ Advisors first reported a position in Gilead Sciences in Q4 2019 and has held it in 10 quarters since.
1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.